Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (21-30 of 418) with videos related to

Pageof 42
Sort By:
Clinical Medicine (London, England)|September 16, 2020
Adrenal insufficiency and checkpoint inhibitors for cancerDaniel L Morganstein, James Larkin
Expert Opinion on Pharmacotherapy|April 29, 2014
New RAF kinase inhibitors in cancer therapyJuan Martin-Liberal, James Larkin
Nature Reviews. Urology|June 3, 2015
Kidney cancer: Carbonic anhydrase IX in resected clear cell RCCLisa M Pickering, James Larkin
The Lancet. Oncology|November 3, 2022
Symptomatic melanoma CNS metastases in the TRICOTEL studyAndreas M Schmitt, James Larkin
Future Oncology (London, England)|February 17, 2015
Vemurafenib for the treatment of BRAF mutant metastatic melanomaJuan Martin-Liberal, James Larkin
Melanoma Management|September 8, 2018
Advances in immunotherapy for melanomaPaolo A Ascierto, James Larkin
Journal of the National Cancer Institute|February 4, 2016
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current PerspectivesMichael B Atkins, James Larkin
BMJ Clinical Evidence|March 23, 2011
Malignant melanoma (metastatic)Rosalie Anne Fisher, James Larkin
The Lancet. Oncology|February 17, 2018
BMI and outcomes in melanoma: more evidence for the obesity paradoxAndrew J Hayes, James Larkin
Current Oncology Reports|February 8, 2011
Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalitiesAxel Bex, James Larkin, Christian Blank
Pageof 42

Showing results (21-30 of 418) with videos related to

Sort By:
Pageof 42
Clinical Medicine (London, England)|September 16, 2020
Adrenal insufficiency and checkpoint inhibitors for cancerDaniel L Morganstein, James Larkin
Expert Opinion on Pharmacotherapy|April 29, 2014
New RAF kinase inhibitors in cancer therapyJuan Martin-Liberal, James Larkin
Nature Reviews. Urology|June 3, 2015
Kidney cancer: Carbonic anhydrase IX in resected clear cell RCCLisa M Pickering, James Larkin
The Lancet. Oncology|November 3, 2022
Symptomatic melanoma CNS metastases in the TRICOTEL studyAndreas M Schmitt, James Larkin
Future Oncology (London, England)|February 17, 2015
Vemurafenib for the treatment of BRAF mutant metastatic melanomaJuan Martin-Liberal, James Larkin
Melanoma Management|September 8, 2018
Advances in immunotherapy for melanomaPaolo A Ascierto, James Larkin
Journal of the National Cancer Institute|February 4, 2016
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current PerspectivesMichael B Atkins, James Larkin
BMJ Clinical Evidence|March 23, 2011
Malignant melanoma (metastatic)Rosalie Anne Fisher, James Larkin
The Lancet. Oncology|February 17, 2018
BMI and outcomes in melanoma: more evidence for the obesity paradoxAndrew J Hayes, James Larkin
Current Oncology Reports|February 8, 2011
Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalitiesAxel Bex, James Larkin, Christian Blank
Pageof 42